The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

  1. Rodríguez, P.C.
  2. Prada, D.M.
  3. Moreno, E.
  4. Aira, L.E.
  5. Molinero, C.
  6. López, A.M.
  7. Gómez, J.A.
  8. Hernández, I.M.
  9. Martínez, J.P.
  10. Reyes, Y.
  11. Milera, J.M.
  12. Hernández, M.V.
  13. Torres, R.
  14. Avila, Y.
  15. Barrese, Y.
  16. Viada, C.
  17. Montero, E.
  18. Hernández, P.
Revista:
Clinical and Experimental Immunology

ISSN: 1365-2249,  0009-9104

Any de publicació: 2018

Volum: 191

Número: 2

Pàgines: 229-239

Tipus: Article

DOI: 10.1111/CEI.13061 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus